Skip to main content
. Author manuscript; available in PMC: 2020 May 7.
Published in final edited form as: Cancer Chemother Pharmacol. 2018 May 25;82(2):211–219. doi: 10.1007/s00280-018-3599-3

Table 1:

Patient characteristics

Patient Age Gender Histology Cohort No. of prior systemic therapies Prior VEGF therapy (Y/N)
1 72 Female Ovarian carcinoma High 6 N
2 57 Female Lung carcinoma High 4 Y
3 57 Female Breast carcinoma Low 6 N
4 47 Female Thyroid carcinoma High 1 Y
5 64 Female Urothelial carcinoma High 2 N
6 71 Male Squamous cell carcinoma Low 4 N
7 65 Female Lung carcinoma Low 1 N
8 67 Male Lung carcinoma Low 2 N
9 54 Female Ovarian carcinoma Low 2 N
10 67 Female Endometrial carcinoma High 5 N
11 56 Female Breast carcinoma Low 11 N
12 65 Male Adenoid cystic carcinoma Low 0 N
13 53 Male Leiomyosarcoma Low 3 N
14 58 Male Unknown primary carcinoma High 0 N